Public Announcement
FOR IMMEDIATE RELEASE
Puresyn and The Progeria Research Foundation Announce Manufacturing Partnership to Advance Therapies for Children and Young Adults with Progeria
MALVERN, PA and PEABODY, MA – April 7, 2026 – Puresyn, a specialized provider of plasmid DNA development and manufacturing services, and The Progeria Research Foundation (PRF), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gilford Progeria Syndrome (Progeria), today announced a manufacturing agreement to advance innovative therapeutic approaches for children and young adults living with this ultrarare and fatal genetic disease, characterized by rapid aging.
The manufacturing agreement brings together Puresyn’s capabilities in high-quality plasmid DNA development and manufacturing with PRF’s world-leading scientific and clinical expertise in Progeria. Plasmid DNA is a foundational component in many advanced therapeutic platforms, including gene therapies.
“Partnering with PRF aligns with our mission to support organizations working on high‑impact therapies for patients with serious and rare diseases,” said Michael Moxley, director of business and process development at Puresyn. “By applying our experience in plasmid DNA manufacturing and quality systems, we aim to help advance PRF’s programs more efficiently and reliably.”
Under the terms of the agreement, Puresyn will provide phase‑appropriate plasmid DNA services to support PRF’s research and development programs, including preclinical and clinical-stage initiatives. The organizations will work closely to optimize plasmid scale-up and manufacturing processes to meet regulatory standards, accelerate timelines, and ensure cost-efficient production.
“Every decision we make at PRF is guided by the children with Progeria and their families,” said Leslie Gordon, M.D., Ph.D., co-founder and medical director of PRF and the mother of Sam Berns who had Progeria. “As we advance gene editing strategies for Progeria into the clinic, manufacturing excellence is essential. We are grateful to partner with Puresyn, whose expertise and commitment to quality give us confidence that promising research can move forward with the rigor and urgency the children deserve, as we race towards the cure.”
The collaboration reflects a shared commitment to addressing the specific needs of ultrarare disease drug development. By leveraging complementary expertise, Puresyn and PRF intend to streamline plasmid manufacturing workflows, reduce operational risk, and build a foundation capable of supporting current programs and future clinical milestones.
About Puresyn
Puresyn is a contract development and manufacturing organization specializing in plasmid DNA services, offering research-grade, INDReady®, and cGMP plasmid production supported by established quality systems and scalable manufacturing infrastructure. Puresyn supports biopharmaceutical and cell and gene therapy companies from early discovery through commercial development with a focus on reliability, technical excellence, and responsive collaboration.
About The Progeria Research Foundation
The Progeria Research Foundation (PRF) is the driving force behind the global effort to understand, treat and ultimately cure children and young adults with Hutchinson-Gilford Progeria Syndrome (Progeria), a rare and fatal genetic disease that causes rapid aging in children. Founded by the family of Sam Berns after his diagnosis in 1999, PRF has enabled or led major scientific breakthroughs in the field; from discovery of the causative gene mutation, to Progeria’s first and only FDA-approved treatment, lonafarnib, to the advancement of gene-editing approaches now in development. Through rigorous science, global research infrastructure and close partnership with the worldwide patient community, PRF is advancing next-generation therapies and leading the Path to Cure Progeria program to determine whether a one-time gene-editing therapy can offer a durable, potentially curative treatment. For more information and to support PRF’s mission, please visit www.progeriaresearch.org.
Media Contacts
The Progeria Research Foundation:
Tracy Lessor
Director of Communications
tlessor@progeriaresearch.org
Puresyn:
Leslie M. Flynn
VP & General Manager
leslie@puresyn.com